Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076285395> ?p ?o ?g. }
- W2076285395 endingPage "139" @default.
- W2076285395 startingPage "133" @default.
- W2076285395 abstract "As regards central nervous system (CNS) effects there are three types of antihistamines. Those that cross the blood-brain barrier and cause widespread impairment of cognitive and psychomotor function; those that cross into the brain and, although without much impairment at low clinical doses, have a dose-related relationship to impairment; and those that do not cross into the brain and therefore possess no intrinsic potential for impairing CNS function.[corrected] To investigate the acute effects of fexofenadine (360 mg) on various aspects of cognitive and psychomotor function in comparison to placebo and promethazine (positive internal control), an antihistamine known to produce psychomotor and cognitive impairment.Fifteen healthy volunteers received fexofenadine 360 mg, promethazine 30 mg and placebo in a 3-way cross-over, double-blind study. For each treatment condition, subjects were required to perform a series of tests of cognitive function and psychomotor performance at baseline and 1, 3, 5 and 7 h post-dose. The test battery consisted of critical flicker fusion (CFF), choice reaction time (CRT), compensatory tracking task (CTT) and a subjective assessment of sedation (LARS).Fexofenadine was not distinguishable from placebo in any of the objective and subjective tests for up to seven hours following drug administration. However, all measures were significantly impaired following the administration of promethazine, which confirms the sensitivity of the test battery for sedation. The effects of fexofenadine and placebo were not significantly different from one another, whereas promethazine caused an overall reduction in CFF thresholds when compared to placebo (P < 0.05). There was an overall significant increase (impairment) in recognition, motor and total reaction time (P < 0.05), and both the tracking accuracy and reaction time aspects of CTT were significantly impaired (P < 0.05) following the administration of promethazine. In contrast, the effects of fexofenadine could not be distinguished from the placebo condition. Subjective ratings of sedation were significantly higher with promethazine when compared to placebo (P < 0.05) and fexofenadine (P< 0.05).Fexofenadine at a dose of 360mg is demonstrably free from disruptive effects on aspects of psychomotor and cognitive function in a study where the psychometric assessments have been shown to be sensitive to impairment, as evidenced by the effects of the verum control promethazine 30 mg. The identification of an antihistamine (fexofenadine) devoid of central effects even at supraclinical doses separates it from currently available first and second generation drugs with no objective evidence of CNS side-effects on cognition and psychomotor function, and highlights the need for the introduction of a third generation of non-sedative antihistamines." @default.
- W2076285395 created "2016-06-24" @default.
- W2076285395 creator A5000987998 @default.
- W2076285395 creator A5067916746 @default.
- W2076285395 creator A5082550430 @default.
- W2076285395 date "2002-01-01" @default.
- W2076285395 modified "2023-10-18" @default.
- W2076285395 title "An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers" @default.
- W2076285395 cites W1528649080 @default.
- W2076285395 cites W1756057165 @default.
- W2076285395 cites W1965397198 @default.
- W2076285395 cites W1973319846 @default.
- W2076285395 cites W1977916033 @default.
- W2076285395 cites W1980421164 @default.
- W2076285395 cites W1988116635 @default.
- W2076285395 cites W1988664394 @default.
- W2076285395 cites W1994657866 @default.
- W2076285395 cites W2012569888 @default.
- W2076285395 cites W2013813784 @default.
- W2076285395 cites W2014530199 @default.
- W2076285395 cites W2016121352 @default.
- W2076285395 cites W2021645020 @default.
- W2076285395 cites W2023346881 @default.
- W2076285395 cites W2023504320 @default.
- W2076285395 cites W2036925181 @default.
- W2076285395 cites W2063178406 @default.
- W2076285395 cites W2066568891 @default.
- W2076285395 cites W2067175241 @default.
- W2076285395 cites W2072883273 @default.
- W2076285395 cites W2074990289 @default.
- W2076285395 cites W2085071824 @default.
- W2076285395 cites W2102707542 @default.
- W2076285395 cites W2135941973 @default.
- W2076285395 cites W2142050681 @default.
- W2076285395 cites W3027688385 @default.
- W2076285395 doi "https://doi.org/10.1046/j.0022-0477.2001.01245.x" @default.
- W2076285395 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12002730" @default.
- W2076285395 hasPublicationYear "2002" @default.
- W2076285395 type Work @default.
- W2076285395 sameAs 2076285395 @default.
- W2076285395 citedByCount "99" @default.
- W2076285395 countsByYear W20762853952012 @default.
- W2076285395 countsByYear W20762853952013 @default.
- W2076285395 countsByYear W20762853952014 @default.
- W2076285395 countsByYear W20762853952016 @default.
- W2076285395 countsByYear W20762853952017 @default.
- W2076285395 countsByYear W20762853952019 @default.
- W2076285395 countsByYear W20762853952020 @default.
- W2076285395 countsByYear W20762853952021 @default.
- W2076285395 countsByYear W20762853952022 @default.
- W2076285395 countsByYear W20762853952023 @default.
- W2076285395 crossrefType "journal-article" @default.
- W2076285395 hasAuthorship W2076285395A5000987998 @default.
- W2076285395 hasAuthorship W2076285395A5067916746 @default.
- W2076285395 hasAuthorship W2076285395A5082550430 @default.
- W2076285395 hasConcept C118552586 @default.
- W2076285395 hasConcept C119599485 @default.
- W2076285395 hasConcept C127413603 @default.
- W2076285395 hasConcept C142724271 @default.
- W2076285395 hasConcept C152484397 @default.
- W2076285395 hasConcept C164953862 @default.
- W2076285395 hasConcept C169900460 @default.
- W2076285395 hasConcept C19743564 @default.
- W2076285395 hasConcept C204787440 @default.
- W2076285395 hasConcept C27081682 @default.
- W2076285395 hasConcept C2776711289 @default.
- W2076285395 hasConcept C2776814716 @default.
- W2076285395 hasConcept C2776880894 @default.
- W2076285395 hasConcept C2778794651 @default.
- W2076285395 hasConcept C2779303165 @default.
- W2076285395 hasConcept C42219234 @default.
- W2076285395 hasConcept C71924100 @default.
- W2076285395 hasConcept C87813604 @default.
- W2076285395 hasConcept C98274493 @default.
- W2076285395 hasConceptScore W2076285395C118552586 @default.
- W2076285395 hasConceptScore W2076285395C119599485 @default.
- W2076285395 hasConceptScore W2076285395C127413603 @default.
- W2076285395 hasConceptScore W2076285395C142724271 @default.
- W2076285395 hasConceptScore W2076285395C152484397 @default.
- W2076285395 hasConceptScore W2076285395C164953862 @default.
- W2076285395 hasConceptScore W2076285395C169900460 @default.
- W2076285395 hasConceptScore W2076285395C19743564 @default.
- W2076285395 hasConceptScore W2076285395C204787440 @default.
- W2076285395 hasConceptScore W2076285395C27081682 @default.
- W2076285395 hasConceptScore W2076285395C2776711289 @default.
- W2076285395 hasConceptScore W2076285395C2776814716 @default.
- W2076285395 hasConceptScore W2076285395C2776880894 @default.
- W2076285395 hasConceptScore W2076285395C2778794651 @default.
- W2076285395 hasConceptScore W2076285395C2779303165 @default.
- W2076285395 hasConceptScore W2076285395C42219234 @default.
- W2076285395 hasConceptScore W2076285395C71924100 @default.
- W2076285395 hasConceptScore W2076285395C87813604 @default.
- W2076285395 hasConceptScore W2076285395C98274493 @default.
- W2076285395 hasIssue "1" @default.
- W2076285395 hasLocation W20762853951 @default.
- W2076285395 hasLocation W20762853952 @default.
- W2076285395 hasOpenAccess W2076285395 @default.
- W2076285395 hasPrimaryLocation W20762853951 @default.